**Supplementary Table 1. Distribution of patient characteristics by PD-L1 and IDO staining**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **PD-L1 Tumor Staining** | |  | **PD-L1 Immune Staining** | |  | **IDO Tumor Staining** | |  | **IDO Immune Staining** | |  |
|  | **Negative** | **Positive** |  | **Negative** | **Positive** |  | **Negative** | **Positive** |  | **Negative** | **Positive** |  |
| **Characteristics** | **n (%)** | **n (%)** | ***P*** | **n (%)** | **n (%)** | ***P*** | **n (%)** | **n (%)** | ***P*** | **n (%)** | **n (%)** | ***P*** |
| **Age at diagnosis, mean (SD)** | 60.3 (10.2) | 58.1 (9.4) | 0.28 | 60.9 (10.9) | 59.2 (9.6) | 0.43 | 60.5 (10.8) | 59.1 (9.4) | 0.45 | 61.4 (10.6) | 58.3 (9.3) | 0.10 |
| **Stage** |  |  |  |  |  |  |  |  |  |  |  |  |
| I-II | 13 (16) | 6 (19) | 0.77 | 2 (7) | 17 (21) | 0.15 | 7 (15) | 12 (19) | 0.59 | 7 (14) | 12 (20) | 0.43 |
| III-IV | 66 (84) | 26 (81) |  | 27 (93) | 65 (79) |  | 40 (85) | 52 (81) |  | 43 (86) | 49 (80) |  |
| Unknown | 1 | 0 |  | 1 | 0 |  | 0 | 1 |  | 1 | 0 |  |
| **Neoadjuvant** **chemotherapy** |  |  |  |  |  |  |  |  |  |  |  |  |
| Yes | 13 (20) | 2 (7) | 0.13 | 5 (22) | 10 (14) | 0.51 | 9 (24) | 6 (11) | 0.09 | 8 (20) | 7 (13) | 0.41 |
| No | 51 (80) | 28 (93) |  | 18 (78) | 61 (86) |  | 28 (76) | 51 (89) |  | 33 (80) | 46 (87) |  |
| Unknown | 19 | 6 |  | 8 | 17 |  | 12 | 13 |  | 11 | 14 |  |
| **Adjuvant chemotherapy** |  |  |  |  |  |  |  |  |  |  |  |  |
| Yes | 55 (90) | 26 (100) | 0.17 | 19 (86) | 62 (95) | 0.17 | 31 (89) | 50 (96) | 0.21 | 35 (88) | 46 (98) | 0.09 |
| No | 6 (10) | 0 (0) |  | 3 (14) | 3 (5) |  | 4 (11) | 2 (4) |  | 5 (13) | 1 (2) |  |
| Unknown | 16 | 2 |  | 7 | 11 |  | 10 | 8 |  | 10 | 8 |  |
| **Residual diseasea** |  |  |  |  |  |  |  |  |  |  |  |  |
| Optimal | 39 (59) | 18 (67) | 0.50 | 14 (61) | 43 (61) | 0.96 | 19 (53) | 38 (67) | 0.18 | 21 (51) | 36 (69) | 0.09 |
| Suboptimal | 27 (41) | 9 (33) |  | 9 (39) | 27 (39) |  | 17 (47) | 19 (33) |  | 20 (49) | 16 (31) |  |
| Unknown | 14 | 5 |  | 7 | 12 |  | 11 | 8 |  | 10 | 9 |  |
| **Survival (years), mean (SD)** | 3.0 (1.5) | 2.8 (1.37) | 0.45 | 3.3 (1.5) | 2.8 (1.4) | 0.07 | 3.0 (1.6) | 2.9 (1.4) | 0.86 | 2.9 (1.5) | 2.9 (1.4) | 0.97 |
| **Vital Status** |  |  |  |  |  |  |  |  |  |  |  |  |
| Deceased | 39 (49) | 8 (25) | 0.02 | 16 (53) | 31 (38) | 0.14 | 26 (55) | 21 (32) | 0.01 | 25 (49) | 33 (36) | 0.17 |
| Alive | 41 (51) | 24 (75) |  | 14 (47) | 51 (62) |  | 21 (45) | 44 (68) |  | 26 (51) | 39 (64) |  |

SD: standard deviation.

aResidual disease is defined as optimal if <1cm tumor diameter after cytoreductive surgery or a CA-125 <35 after the last cycle of the first round of adjuvant chemotherapy.